The amount of omics data in the public domain is increasing every year [1, 2]. Public availability of datasets is growing in all disciplines, because it is considered to be a good scientific practice (e.g. to enable reproducibility), and/or it is mandated by funding agencies, scientific journals, etc. Science is now a data intensive discipline and therefore, new and innovative ways for data management, data sharing, and for discovering novel datasets are increasingly required [3, 4]. However, as data volumes grow, quantifying its impact becomes more and more important. In this context, the FAIR (Findable, Accessible, Interoperable, Reusable) principles have been developed to promote good scientific practises for scientific data and data resources [5]. In fact, recently, several resources [1, 2, 6] have been created to facilitate the Findability (F) and Accessibility (A) of biomedical datasets. These principles put a specific emphasis on enhancing the ability of both individuals and software to discover and re-use digital objects in an automated fashion throughout their entire life cycle [5]. While data resources typically assign an equal relevance to all datasets (e.g. as results of a query), the usage patterns of the data can vary enormously, similarly to other "research products" such as publications. How do we know which datasets are getting more attention? More generally, how can we quantify the scientific impact of datasets?
indeed increasingly relevant for individuals, but also reporting aggregated information has become essential in the case of research groups, scientific consortia, institutions or for public data resources among others, in order to assess the level of importance, excellence and relevance of their work. This is a key piece of information for funding agencies, which is used routinely to prioritize the projects and resources they fund. However, most of the efforts nowadays focus on the evaluation and quantification of the impact of publications as the main artefact. For instance, in 2013, the "altmetrics" team proposed a set of 'alternative' metrics to trace research products with special focus on publications [10] . Specific tools and services have been built since to aggregate "altmetrics", including for instance counts of mentions of a given publication in blog posts, tweets and articles in mainstream media. The "altmetrics" score is widely used by the research community nowadays (e.g. by multiple scientific journals), as a measure of scientific impact. In addition to the traditional journals, a relatively recent trend has been the introduction of pre-print servers in the biological/biomedical field (e.g. bioRxiv), supporting the pre-publication of manuscripts which are usually under review in traditional journals. Pre-prints are increasingly tracked and recognised as research products (e.g. by funding agencies such as The Wellcome Trust).
However, adequate tracking and recognition of datasets has been limited so far for multiple reasons: i) the relatively low number of publications citing datasets instead of their corresponding publications; ii) the lack of services that store and index datasets from heterogeneous origins; and iii) the absence of widely-used metrics that enable the quantification of their impact. Some attempts have been made to improve the situation, by introducing DOIs (Data Object Identifiers) directly associated to datasets [11] .
In 2016, we released the first version of the Omics Discovery Index (OmicsDIwww.omicsdi.org) as a light-weight system to aggregate datasets across multiple public omics data resources. OmicsDI integrates genomics, transcriptomics, proteomics, metabolomics, and multi-omics datasets, as well as computational models of biological processes [1] . The OmicsDI web interface and Application Programming Interface (API) provide different views and search capabilities on the indexed datasets. Datasets can be searched and filtered based on different types of technical and biological annotations (e.g., species, tissues, diseases, etc.), year of publication, and the original data repository where they are stored, among others. At the time of writing (March 2018), OmicsDI stores just over 100,000 datasets from 16 different public data resources (www.omicsdi.org/database). The split per omics technology is as follows: transcriptomics (68,648 datasets), genomics (12, 274) , proteomics (9,352), metabolomics (1,679), multi-omics (4,057) and biological models (8, 418) . Here, we propose a set of novel metrics to quantify the impact of biomedical datasets. A complete framework (now integrated in OmicsDI) has been implemented in 3 order to provide and evaluate those metrics. Finally, we propose a set of recommendations for authors, journals, and data resources to promote an optimal quantification of the impact of datasets.
Online Methods
In contrast to publications, where the impact is mainly measured by the number of citations, we believe the impact of datasets should be quantified using more than one metric. With this in mind, we have 
Proposed platform to quantify dataset impact
In order to compute the proposed metrics (Reanalyses, Citations, Connections), a novel platform has been developed within OmicsDI. Figure 1 shows a schematic representation of the platform. OmicsDI imports the metadata for each dataset from the original providers, using the OmicsDI XML file format ( Fig. 1a ) [1] . In order to ensure that the metrics are accurate, the infrastructure implements a system to remove dataset redundancy (when two different resources store the same original dataset). An automatic pipeline and a manual annotation system enable OmicsDI to remove duplicated datasets with potentially different identifiers (e.g. transcriptomics datasets available in ArrayExpress and Gene Expression Omnibus (GEO)) ( Fig. 1b) . The pipeline ( Fig. 1b) designates one of the datasets as the canonical representation and annotates the rest of identifiers as additional secondary ones (Supplementary Note 1).
By March 2018, 35 knowledge-bases were used to identify and count the number of biological connections (Supplementary Note 2) . Each tracked biological entity available in the knowledge-bases includes a cross-reference to original datasets ( Fig. 1c) . Then, a software component in OmicsDI navigates this information and computes the connections for each of them. The implementation of the reanalysis metric is possible because the OmicsDI XML schema (https://github.com/OmicsDI/specifications) provides a mechanism to define when a dataset is based on another one. Finally, the citations metric is computed by parallel calls to the EuropePMC API (europepmc.org/RestfulWebService) [17] and the annotation of the final counts for each dataset. All these pipelines and software components 5 can scale to handle thousands of datasets and systematically compute and update the metrics on a weekly basis (github.com/OmicsDI/index-pipeline).
Dataset Claiming Component
Analogously to services such as Google Scholar and ResearchGate for publications, we have implemented a mechanism that enables researchers to create their own profile in 
Results
The reanalyses metric quantifies how many times one dataset has been re-used (reanalysed) and the result deposited in the same or in another resource. By March 2018, the number of datasets that have been reanalysed at least once is 8,000. The number of reanalyses varies depending on each field and on the existing integration among databases.
For example, on average BioModels models are reused 0.8 times, whereas PRIDE (proteomics), MassIVE (proteomics) and ArrayExpress (transcriptomics) datasets are reused 0.12, 0.01 and 0.18 times, respectively.
6 BioModels MODEL1402200003 ("Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease") [24] is the most re-used "dataset" (the concept of dataset in OmicsDI is extended to biological models), with 6,691 reuses made available in the same BioModels resource. However, it should be noted that all re-uses are associated with a single publication [25] , in which patient data was used to parameterise MODEL1402200003 to 6,691 instances. Frequently, dataset re-use is a hierarchical process, where one dataset is reanalysed subsequently multiple times. . In contrast to biological models, the proteomics and transcriptomics fields are still working to define a proper mechanism to report the multiple reanalysis of datasets in a hierarchical manner [11] . Interestingly, the distribution of the elapsed time between the year of publication of the original datasets and publication of the reanalyses shows that most of the datasets are reanalysed within one year after publication ( Fig. 3a) . In fact, three years after the release date, typically the number of reanalyses decrease significantly, making this a metric better suited to measure immediate impact.
The second metric is the number of direct citations in publications for each dataset as previously suggested [16] . We obtained this information from the EuropePMC API. ArrayExpress (transcriptomics), EGA (genomics/transcriptomics), PRIDE (proteomics) and
BioModels (models) is 3.4 (9.8), 2.5 (7.2), 4.2 (0.8) and 1.2 (0.66), respectively. Interestingly, the standard deviation indicates that in transcriptomics -GEO (9.8) and ArrayExpress (7.2)some datasets get significantly more attention from the community than others, whereas for proteomics datasets -PRIDE (0.8) -the citation rate is much more homogenous.
The current workflow searches EuropePMC using all the identifiers associated with a given dataset (e.g. a given dataset can be cited in a publication using the ArrayExpress, GEO or BioProject identifiers 
Discussion
One of the obstacles to achieving a systematic deposition of datasets in public repositories is the lack of a broad scientific reward system, considering other research products in addition to scientific publications [7] . Different studies have demonstrated the need for metrics and frameworks to quantify the impact of deposited datasets in the public domain [7, 16, 23 ]. Such a system would not only encourage authors to make their data public, but also help funding agencies, biological resources and the scientific community as a whole to focus on the most impactful datasets. In OmicsDI we have implemented a novel platform to quantify the impact of public datasets systematically, by using data from biological data resources (reanalyses), literature (citations), and knowledge-bases (connections). Every metric is updated on a weekly basis and made available through the OmicsDI web interface and API (http://www.omicsdi.org/ws/).
One of the primary findings is that in systems biology (the BioModels database is the representative resource), the deposition of data has enabled systematically generation of new knowledge (biological models), based on previous datasets. For example, the model "Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease" (MODEL1402200003) [24] has been used to build more than 6,000 models available in BioModels. Moreover, the results showed that the reanalyses metric is crucial to highlight relevant datasets early after the dataset release ( Fig. 2c) . 8,000
datasets (>5% of OmicsDI) have been reanalysed by resources such as PeptideAtlas, GPMDB, or the EBI Expression Atlas, among others. However, it should be noted that the reanalyses metric measures only the impact of datasets in the same or other data resources contributing their metadata to OmicsDI, which constitutes a fraction of the total re-use by the scientific community.
To complement the reanalysis metric, we counted direct citations of datasets in scientific publications. Different studies have estimated that the proportion of the total citation count contributed by data depositions is around 6-20% [10, 16] 513 is among the 10 most cited datasets in the literature, which has been cited 155 times, and reanalysed 4 times. We have decided to only compute and provide these "raw" metrics to the community, rather than combining them into more complex models [32, 33] . However, we have shown that these metrics can be used independently to generate models for classification (Supplementary Note 4) [34].
In 2011, Mons et al. introduced the idea of nano-publications, from where the authors could get credit not only through the actual publication but also through all the knowledge associated with it [7] . In our view, the value of the dataset should not be only associated with the "raw data" or the claims in the publication, but also should be assessed considering all the biological entities supported in knowledge-bases. We have developed the connections metric ( Fig. 3d) , which can be used to estimate the impact of a dataset for knowledgebases, by counting how many biological entities are supported by it.
In addition to the three-metrics used to measure impact, it should be highlighted that
OmicsDI routinely uses the number of views/accesses available for each dataset in the resource to rank the results of a search query, using information available from the interaction of other researchers with the indexed datasets. In this context, OmicsDI is monitoring not only the web interface views but also the interaction through the OmicsDI API. In average, every dataset in OmicsDI has been accessed at least 30 times since 2016
(Supplementary Note 5). In our view, the number of views/accesses in OmicsDI can be used as a proxy for other relevant metrics such as volume of downloads and number of views in the original data resources. These metrics coming from the original data resources are normally not made publicly available and at present infeasible to retrieve. In fact, at present the first coordinated efforts to gather them in a standard manner are taking place in the context of the ELIXIR framework for European biological data resources [35] .
The newly implemented OmicsDI dataset claiming system enables authors, research groups, scientific consortia and research institutions to organize datasets under a unique OmicsDI profile, and for datasets to be added to their own ORCID profiles as well. At the time of writing (March 2018), more than 200 datasets have been claimed into ORCID profiles through OmicsDI. In our view, following the same system for monitoring the impact of individual datasets, these metrics could also be used to measure at least some aspects of the impact of public omics data resources [36, 37] . By March 2018, GEO, PRIDE and
MetaboLights datasets are the most cited, re-used, and connected in their transcriptomics, proteomics and metabolomics, respectively (Figure 3) . A common problem of impact evaluation is to compare different fields or topics with the same metrics [38] . Therefore, we Note 7) . Indeed, many databases reference only the associated publications, rather than the actual dataset identifiers. In fact, the correct tracking of datasets in a database by other data resources can help to assess its impact, since it demonstrates that the data they store is actively re-used by (and thus relevant to) the community. Naturally, the same effort should also be made by knowledge bases (e.g.
resources including pathways, interactions, gene/protein profiles, etc), to reference the original datasets rather than the publications, in order to recognize that a large part of the biological knowledge is derived from the actual datasets.
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We envision that as more and more data is made publicly available, more standardization will be implemented to cross-link resources, manuscripts, datasets and the final biological molecules, making the proposed framework more robust. We expect that any mature omics field should welcome novel insights that can be derived from existing datasets and promote their traceability. We all "stand on the shoulders of giants". We expect that an improved quantitation of the impact of datasets will help scientists, funders, and research organisations to better value a broader range of "giants" (research products). Connections are computed using the biological entities stored in knowledge-bases. 
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